In a first trial after infusion of donor mature NK cells followed by administration of IL-2 daily for 14 days, a successful donor NK-cell expansion was observed for patients previously treated with cyclophosphamide and fludarabine [107,108], thus allowing the achievement of complete remission in 30% of poor prognosis AML patients. The gene discussed is IL2; the disease is acute myeloid leukemia.